文献速递心力衰竭与心肌病心律失常

多重合并症与心脏再同步治疗反应:MADIT-CRT长期随访

Multiple Comorbidities and Response to Cardiac Resynchronization Therapy: MADIT-CRT Long-Term Follow-Up.
PubMed 文献 · J Am Coll Cardiol · 2017-01-01

本研究基于MADIT-CRT试验中1214例左束支传导阻滞(LBBB)患者,评估合并症负担与心脏再同步治疗除颤器(CRT-D)对比埋藏式心律转复除颤器(ICD)疗效的关系。平均随访4.65年,合并症负担与死亡或非致命心衰事件风险增加相关(p<0.001),但合并症负担与CRT-D相比ICD的获益无交互作用(交互p=0.943)。合并症负担不影响CRT-D相比ICD的临床获益。

要点

  • 合并症负担越重,左室逆重构改善程度越差。
  • 合并症负担增加与死亡或非致命心衰事件风险升高相关(p<0.001)。
  • 合并症负担与CRT-D相比ICD的获益无交互作用(交互p=0.943)。

核心结论

  • 在MADIT-CRT研究的LBBB患者长期随访中,合并症负担不影响CRT-D相比ICD的临床获益。

研究设计与样本

  • 研究纳入MADIT-CRT研究中1214例LBBB患者,按合并症数量分为0、1、2或≥3个合并症组。
  • 合并症包括肾功能不全、高血压、糖尿病、冠心病、房性心律失常史、室性心律失常史、当前吸烟和脑血管意外。

主要发现

  • 合并症负担与左室收缩末期容积、左室舒张末期容积、左室射血分数、左房容积和左室不同步的改善呈负相关。
  • 校正模型中,无论治疗分组,随着合并症负担增加,死亡或非致命心衰事件风险增加(p<0.001)。
  • 平均随访4.65年,合并症负担与CRT-D相比ICD仅对死亡或非致命心衰事件的获益无交互作用(交互p=0.943)。
  • 在合并症负担最重的组(2和≥3个),CRT-D相比ICD的绝对风险降低似乎大于合并症负担较轻的组(0和1个)。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Data regarding cardiac resynchronization therapy (CRT) in patients with multiple comorbidities are limited. OBJECTIVES: This study evaluated the association of multiple comorbidities with the benefits of CRT over implantable cardioverter-defibrillator (ICD) alone. METHODS: We examined 1,214 MADIT-CRT (Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy) study patients with left bundle branch block (LBBB) and 0, 1, 2, or ≥3 comorbidities, including renal dysfunction, hypertension (HTN), diabetes, coronary artery disease, history of atrial arrhythmias, history of ventricular arrhythmias, current smoking, and cerebrovascular accident. In an adjusted analysis, we analyzed risk of heart failure (HF) events or death by comorbidity group in all patients and in patients with CRT with defibrillator (CRT-D) versus ICD. Then we examined percent change in left ventricular (LV) end-diastolic volume, LV end-systolic volume, LV ejection fraction, left atrial volume, and LV dyssynchrony at 1-year in CRT-D patients by comorbidity group. RESULTS: There was an inverse relationship between comorbidity burden and improvements in LV end-systolic volume, LV end-diastolic volume, left ventricular ejection fraction, left atrial volume, and LV dyssynchrony. In an adjusted model, there was an increasing risk of death or nonfatal HF events with increasing comorbidity burden regardless of treatment group (p < 0.001). During a mean follow-up of 4.65 years, there was no interaction with respect to comorbidity burden and the benefit of CRT-D versus ICD only for death or nonfatal HF events (interaction p = 0.943). In the groups with greatest comorbidity burden (2 and ≥3), the absolute risk reduction associated with CRT-D over ICD alone appeared greater than that seen for groups with less comorbidity burden (0 and 1). CONCLUSIONS: During long-term follow-up of MADIT-CRT study patients with LBBB randomized to CRT-D, there were differences in HF or death risk and in the degree of reverse remodeling among comorbidity groups. However, the burden of comorbidity does not appear to compromise the clinical benefits of CRT-D compared with ICD alone.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Zeitler EP, Friedman DJ, Daubert JP, et al. Multiple Comorbidities and Response to Cardiac Resynchronization Therapy: MADIT-CRT Long-Term Follow-Up. J Am Coll Cardiol. 2017. PMID: 28494974. doi:10.1016/j.jacc.2017.03.531

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。